Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial

Saroglitazar, being a dual PPAR-α/γ agonist, has shown beneficial effect in diabetic dyslipidemia and hypertriglyceridemia. Fibrates are commonly used to treat severe hypertriglyceridemia. However, the effect of saroglitazar in patients with moderate to severe hypertriglyceridemia was not evaluated....

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Gutierrez, Rene, González, Jose Gerardo, Parmar, Deven, Shaikh, Farheen., Cruz-López, Pio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240860/
https://www.ncbi.nlm.nih.gov/pubmed/35605678
http://dx.doi.org/10.1016/j.jlr.2022.100233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240860/
https://www.ncbi.nlm.nih.gov/pubmed/35605678
http://dx.doi.org/10.1016/j.jlr.2022.100233

Ejemplares similares